About Nuvectis Pharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://nuvectis.com/
Frequently Asked Questions
What is the 52-week range for NVCT?
The 52-week high is $29.275 and the 52-week low is $5.55.
What is the P/E ratio for NVCT?
The P/E ratio data is currently unavailable.
What is the dividend yield for NVCT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -169.47%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 10.50.
Analyst Recommendation Trends
Wall Street analyst consensus for NVCT over the last few months:
Latest NVCT News
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or prog
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.
Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today
NVCT stock surged on NXP100 PNH deal. Explore catalysts, dilution risk, and pipeline outlook for NXP100/NXP200/NXP900âread the NVCT hold thesis now.
This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Analysts downgraded UiPath, Cal-Maine with several price-target cuts.
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast li
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. | +30,000 | - | - |
| 2026-06-30 | Mosseri Marlio Charles | +50,000 | $18.32 | $916,000 |
| 2026-06-30 | BENTSUR RON | +12,500 | $20 | $250,000 |
| 2026-06-11 | Sanchez Juan | +35,000 | - | - |
| 2026-06-11 | Kaplan Matthew L. | +35,000 | - | - |
| 2026-06-11 | Hoberman Kenneth | +35,000 | - | - |
| 2026-06-11 | Oliviero James F III | +35,000 | - | - |
| 2026-01-06 | Shemesh Shay | +150,000 | - | - |
| 2026-01-06 | Poradosu Enrique | +150,000 | - | - |
| 2026-01-06 | Carson Michael J. | +61,200 | - | - |
| 2026-01-06 | BENTSUR RON | +150,000 | - | - |
| 2025-11-05 | Sanchez Juan | +13,000 | $5.79 | $75,270 |
| 2025-11-05 | Kaplan Matthew L. | +11,000 | $5.84 | $64,240 |
| 2025-11-05 | BENTSUR RON | +5,000 | $5.72 | $28,600 |
| 2025-10-27 | Mosseri Marlio Charles | +72,836 | $6.28 | $457,410 |
| 2025-10-24 | Mosseri Marlio Charles | +35,034 | $6.15 | $215,459 |
| 2025-10-23 | Mosseri Marlio Charles | +46,900 | $6.06 | $284,214 |